The Oncology Institute, Inc. (TOIIW)
| Market Cap | 458.92M +87.4% |
| Revenue (ttm) | 545.76M +35.4% |
| Net Income | -36.32M |
| EPS | -0.37 |
| Shares Out | 99.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,593 |
| Open | 0.0478 |
| Previous Close | 0.0530 |
| Day's Range | 0.0478 - 0.0600 |
| 52-Week Range | 0.0250 - 0.2725 |
| Beta | 0.36 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About TOIIW
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliativ... [Read more]
News
The Oncology Institute Chief Medical Officer to Speak on Value-Based Specialty Care at APG Spring Conference
CERRITOS, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Yale D.
The Oncology Institute Slides: Investor presentation
The Oncology Institute has posted slides in relation to its latest quarterly earnings report, which was published on May 20, 2026.
The Oncology Institute to Participate in B. Riley Securities Institutional Investor Conference
CERRITOS, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virn...
Oncology Institute Q1 Earnings Call Highlights
Oncology Institute NASDAQ: TOI reported a strong start to 2026, with first-quarter revenue rising 41% year over year as the company expanded value-based care arrangements and posted record specialty p...
The Oncology Institute Earnings Call Transcript: Q1 2026
Q1 2026 saw 41% revenue growth, record specialty pharmacy performance, and profitability in Florida. Guidance for revenue, adjusted EBITDA, and free cash flow was reaffirmed or raised, with ongoing expansion in value-based contracts and AI-driven efficiencies.
The Oncology Institute Quarterly report: Q1 2026
The Oncology Institute has published its Q1 2026 quarterly earnings report on May 7, 2026.
The Oncology Institute Earnings release: Q1 2026
The Oncology Institute released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
The Oncology Institute Reports First Quarter 2026 Financial Results
CERRITOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, t...
Constellation Software Inc. and Topicus.Com Inc. Announce Results for Topicus.com Inc. for the First Quarter Ended March 31, 2026
TORONTO, May 05, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) in a joint release with Constellation Software Inc. (TSX:CSU) today announced financial results for Topicus.com Inc. (“Topicus” or...
The Oncology Institute Proxy statement: Proxy filing
The Oncology Institute filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
The Oncology Institute Proxy statement: Proxy filing
The Oncology Institute filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
The Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference Call
CERRITOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) a pioneer in value-based community oncology care, today announced that the company will release ...
The Oncology Institute Transcript: 25th Annual Needham Virtual Healthcare Conference
A value-based oncology provider is expanding rapidly through delegated contracts, especially in Florida, and expects significant growth in capitated revenue and profitability through 2028. The dispensary segment has become the largest revenue driver, and AI initiatives are set to enhance efficiency and margins.
Oncology Institute names Minh Merchant Chief Legal Officer
The Oncology Institute (TOI) announced that Minh Merchant has joined the organization as Chief Legal Officer. In this role, Merchant will oversee legal, regulatory, compliance and privacy functions as...
Oncology Institute price target raised to $8 from $6 at B. Riley
B. Riley raised the firm’s price target on Oncology Institute (TOI) to $8 from $6 and keeps a Buy rating on the shares. Oncology Institute delivered its first profitable quarter…
The Oncology Institute Slides: Investor presentation
The Oncology Institute has posted slides in relation to its latest quarterly earnings report, which was published on March 13, 2026.
The Oncology Institute Earnings Call Transcript: Q4 2025
Achieved first profitable quarter on adjusted EBITDA in Q4 2025, with revenue up 28% year-over-year and strong growth in pharmacy and capitated care. 2026 guidance projects continued revenue and margin expansion, with positive free cash flow expected by year-end.
The Oncology Institute Annual report: Q4 2025
The Oncology Institute has published its Q4 2025 annual report on March 12, 2026.
The Oncology Institute Earnings release: Q4 2025
The Oncology Institute released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026
CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States,...
Oncology Institute appoints Kim Tzoumakas to board of directors
The Oncology Institute (TOI) announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas is CEO for VytlOne National Pharmacy Service. Published fi...
U.S. Neurology Associates Partners with M33 Growth to Transform Neurological Care
DALLAS and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- M33 Growth, a Boston-based venture and growth-stage investment firm, today announced its partnership with U.S. Neurology Associates (“USNA” or the ...
Oncology Institute promotes Panda to CIO, Mariano to CPO
The Oncology Institute (TOI) announced the promotions of Rakesh Panda to Chief Information Officer, CIO, and Nolan Mariano to Chief People Officer, CPO.
The Oncology Institute Announces Leadership Promotions
Rakesh Panda appointed Chief Information Officer Nolan Mariano appointed Chief People Officer CERRITOS, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) announced t...
Oncology Institute appoints Mark Stolper to board of directors
The Oncology Institute (TOI) announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadersh...